{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:46:31Z","timestamp":1747226791377,"version":"3.40.5"},"reference-count":13,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>The rate of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection and immunogenicity of a single dose of ChAdOx1 vaccine at 16 weeks post-vaccination among young and healthy participants remains unclear in Saudi Arabia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Assess the rate of subsequent infection and immunogenicity of a single dose of ChAdOx1 vaccine at 16 weeks post-vaccination in a sample of healthy and young participants.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Cross-sectional study<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Academic teaching hospital in Riyadh, Saudi Arabia<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SUBJECTS AND METHODS:<\/jats:title>\n            <jats:p>Healthy participants 18\u201350 years of age, who received one dose of ChAdOx1 vaccine and had no history of SARS CoV-2 infection were recruited, and blood samples were obtained 16 weeks after vaccination to assess immunogenicity using a commercially available kit.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n            <jats:p>The rate of SARS-CoV-2 infection within 16 weeks post-vaccination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SAMPLE SIZE:<\/jats:title>\n            <jats:p>385 participants with median (IQR) age of 34 (29-38) years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>\n              Eleven (2.8%) participants acquired polymerase chain reaction (PCR)-confirmed infection within 16 weeks after a single dose of ChAdOx1 vaccine (mean [SD] 42.5 [28] days post-vaccination). No hospital or intensive care unit admissions occurred among the subjects in this sample. Females were significantly over-represented in PCR-confirmed cases of SARS-CoV-2 infection, with 10 of 11 infections occurring in females (\n              <jats:italic>P<\/jats:italic>\n              =.006). Antibody response against anti-spike IgG were detectable in 92.7% of subjects at 16 weeks\u2019 post-vaccination. The median anti-spike IgG level after vaccination was 273.1 (IQR 107-1052 AU\/mL). However, the anti-nucleocapsid IgG antibody demonstrated a sensitivity of only 20%.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>A single dose of ChAdOx1 vaccine in healthy and young individuals was associated with a low, single-digit rate of PCR-confirmed infection, most of which were mild.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LIMITATIONS:<\/jats:title>\n            <jats:p>Small sample size and single-center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONFLICT OF INTEREST:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>","DOI":"10.5144\/0256-4947.2022.223","type":"journal-article","created":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T10:38:07Z","timestamp":1659868687000},"page":"223-228","source":"Crossref","is-referenced-by-count":0,"title":["Outcome after single dose of ChAdOx1 vaccine against SARS-CoV-2 infection at 16 weeks post-vaccination among healthy adults in Saudi Arabia"],"prefix":"10.5144","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7664-8044","authenticated-orcid":true,"given":"Ahlam","family":"Alghamdi","sequence":"first","affiliation":[{"name":"From the Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia"},{"name":"From the Department of Pharmacy, King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser","family":"Alsanea","sequence":"additional","affiliation":[{"name":"From the Department of Surgery, Alfaisal University, King Faisal Specialist Hospital and Research Centre, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alraey","sequence":"additional","affiliation":[{"name":"From the Infectious Diseases Department, King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy","family":"Joseph","sequence":"additional","affiliation":[{"name":"From the Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Aboud","sequence":"additional","affiliation":[{"name":"From the Infectious Diseases Department, King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamer","family":"Almangour","sequence":"additional","affiliation":[{"name":"From the Department of Pharmacy, King Abdullah bin Abdulaziz Unviversity Hospital, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasaef","family":"Alharbi","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine, King Abdullah bin Abdulaziz Unviversity Hospital, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hind","family":"Alhumidan","sequence":"additional","affiliation":[{"name":"From the Department of Pathology and Laboratory Medicine, King Abdullah bin Abdulaziz Unviversity Hospital, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalrhman","family":"Alanizi","sequence":"additional","affiliation":[{"name":"From the Department of Pharmacy, King Abdullah bin Abdulaziz University Hospital, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Al-jedai","sequence":"additional","affiliation":[{"name":"From the College of Pharmacy and College of Medicine, Alfaisal University. Riyadh, Saudi Arabia"},{"name":"From the Therapeutics Affairs, Ministry of Health, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3134","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury DS","year":"2021","unstructured":"Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 May;27:1205\u201311.","journal-title":"Nat Med"},{"issue":"10275","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Gam-COVID-Vac Vaccine Trial Group Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov DY","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AL, Zubkova OV, Dzharullaeva AS, et al. Gam-COVID-Vac Vaccine Trial Group Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 2;397(10275):671\u201381.","journal-title":"Lancet"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Parry HM Bruton R Tut G Ali M Stephens C Faustini S et al. Single Vaccination with BNT162b2 or ChAdOx1 in Older People Induces Equivalent Antibody Generation but Enhanced Cellular Responses after ChAdOx1. SSRN [Preprint]. 2021 [cited 2021 November 20]. Available from: 10.2139\/ssrn.3825573","DOI":"10.2139\/ssrn.3825573"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Bernal JL Andrews N Gower C Stowe J Robertson C Tessier E et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease hospitalisations and mortality in older adults in England. medRxiv 21252652 [Preprint]. 2021 [cited 2021 November 20]. Available from: 10.1101\/2021.03.01.21252652","DOI":"10.1101\/2021.03.01.21252652"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 10;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley SF","year":"2021","unstructured":"Lumley SF, O\u2019Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Oxford University Hospitals Staff Testing Group. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021 Feb;11;384:533\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2666-5247(21)00275-5","article-title":"T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study","volume":"3","author":"Angyal A","year":"2022","unstructured":"Angyal A, Longet S, Moore S, Payne RP, Harding A, Tipton T, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: a multicentre, prospective, observational cohort study. Lancet Microbe. 2022 Jan;3(1):e21\u2013e31.","journal-title":"Lancet Microbe"},{"issue":"11","key":"e_1_3_2_9_2","first-page":"2065","article-title":"Age-dependent immune response to the Biontech. Pfizer BNT162b2 COVID-19 vaccination","volume":"73","author":"M\u00fcller L","year":"2021","unstructured":"M\u00fcller L, Andr\u00e9e M, Moskorz W, Drexler I, Walotka L, Grothmann R, et al. Age-dependent immune response to the Biontech. Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021 Dec 1;73(11):2065\u201372.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.tjog.2020.09.006","article-title":"A review of vaccine effects on women in light of the COVID-19 pandemic","volume":"59","author":"Chang WH","year":"2020","unstructured":"Chang WH. A review of vaccine effects on women in light of the COVID-19 pandemic. Taiwan J Obstet Gynecol. 2020 Sep 11;59(6):812\u201320","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"9","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom","volume":"6","author":"Wei J","year":"2021","unstructured":"Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat Microbiol. 2021 Sep;6(9):1140\u20139.","journal-title":"Nat Microbiol"},{"issue":"10","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein SL","year":"2016","unstructured":"Klein SL, Flanagan KL, Plebanski M, Klein SL. Sex differences in immune responses. Nat Rev Immunol. 2016 Oct;16(10):626\u201338.","journal-title":"Nat Rev Immunol"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Choudhary HR Parai D Dash GC Peter A Sahoo SK Pattnaik M et al. IgG antibody response against Nucleocapsid and Spike protein post SARS-CoV-2 infection. Res Sq [Preprint]. 2021 [cited 2021 November 20]. Available from: 10.21203\/rs.3.rs-490375\/v1","DOI":"10.21203\/rs.3.rs-490375\/v1"},{"issue":"24","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin EG","year":"2021","unstructured":"Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021 Oct 6;385(24), e84.","journal-title":"N Engl J Med"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,8,7]],"date-time":"2022-08-07T10:38:52Z","timestamp":1659868732000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2022.223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.5144\/0256-4947.2022.223"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2022.223","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"type":"print","value":"0256-4947"},{"type":"electronic","value":"0975-4466"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}